The final clinical trials of the new AstraZeneca anti-Coronavirus drug, AZD7442, showed its strong efficiency in the long term, Al Ain reported on Friday.
AstraZeneca's newly developed drug is based on combining two different kinds of antibodies to be taken by the unvaccinated persons to give them the required protection and efficiency. In addition, it can reduce the possibility of risky symptoms and COVID-19 related death risks.
Conducted for six months, the pre-final stage experiments: " showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination," according to a statement released by the drugmaker.
One 300 mg dose succeeded in reducing the risk of developing COVID-19 fatal symptoms by 83%, in addition, no severe COVID-19 related infections were recorded among the 73% of the participants when they faced high-risk infection conditions.
In the same context, another trial was dedicated to testing the impact of the new drug for mild and moderate symptoms.
It shows that the 600 mg dose could reduce the development of those symptoms by 88%
Hugh Montgomery, professor of intensive care medicine at University College London, explained: "These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives."
He added: "Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination."
The leading drug manufacturer is expected to submit the latest results for the US Food and Drug Authority (FDA).
Follow the latest news on Google News
